Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Clinical, Instrumental, and Prognostic Definitions of de novo Central Nervous System Demyelinating Disorders Following Immune Checkpoint Inhibitor Therapy

Author:Masciocchi, Stefano   Malvaso, Antonio   Bihan, Kevin   Dinoto, Alessandro   Farina, Antonio   Picca, Alberto   Izquierdo Gracia, Cristina   Martín-Aguilar, Lorena   Bruna-Escuer, Jordi   Damato, Valentina   Sechi, Elia   Rossi, Simone   De Rossi, Nicola   Ariño, Helena   Cobo-Calvo, Alvaro   Mariotto, Sara   Joubert, Bastien   Marchioni, Enrico   Vogrig, Alberto   Gastaldi, Matteo   

Session Name:P6: Autoimmune Neurology: Immune Checkpoint Inhibitor and CAR-T 1  

Topic:Autoimmune Neurology  

Program Number:P6.001  

Author Institution:Neuroimmunology Laboratory and Neuroimmunology Research Section, IRCCS Mondino Foundation, Pavia, Italy, Italy  Department of Pharmacology, Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hôpitaux de Paris (AP-HP), Clinical Investigation Center (CIC-1901), Sorbonne Université, Pitié-Salpêtrière Hospital, Paris, France, France  Neuroimmunology and Neuromuscular Disease Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, Italy  French Reference Centre on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, 59 Boulevard Pinel, 69677, Bron Cedex, France, France  Neuro-Oncology Service, AP-HP, Pitié-Salpêtrière Hospital and Sorbonne Université, Paris, France, France  Multiple Sclerosis Unit, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain, Spain  Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Spain  Neuro-Oncology Unit, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain, Italy  Department of Neuroscience, University of Florence, Florence, Italy  University of Sassari, Sassari, Italy  IRCCS Istituto delle Scienze Neurologiche di Bologna (S.R., R.R., M. Guarino), Italy, Italy  ASST-Spedali Civili di Brescia, Montichiari, Italy, Italy  Neurology Department, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona, Spain, Spain  Neurology Unit, University of Verona, Verona, Italy  Hospices Civils de Lyon, Saint-Genis-Laval, France  Neuroncology and Neuroinflammation Unit, IRCCS Mondino Foundation, Pavia, Italy, Pavia, Italy  Department of Medicine (DMED), University of Udine, Udine, Italy  Clinical Neurology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Italy  IRCCS Mondino Foundation, Pavia, Italy  

Efficacy and Safety of Frexalimab in Participants With Relapsing Multiple Sclerosis: 3-Year Results From the Phase 2 Open-label Extension

Author:Vermersch, Patrick   Krieger, Stephen   Wiendl, Heinz   Granziera, Cristina   Mao-Draayer, Yang   Cutter, Gary   Kalbus, Oleksandr   Staikov, Ivan   Dufek, Michal   Montalban, Xavier   Saubadu, Stephane   Luo, Xiaodong   Smyth, Brendan   Djukic, Biljana   Truffinet, Philippe   Wallstroem, Erik   Giovannoni, Gavin   

Session Name:P7: Multiple Sclerosis: Clinical Trials 1  

Topic:Multiple Sclerosis  

Program Number:P7.003  

Author Institution:University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France, Lille, France  Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY, United States, New York, NY  Department of Neurology and Neurophysiology, University of Freiburg, Freiburg, Germany  Brain & Mind Institute, University of Sydney, Sydney, Australia, Freiburg im Breisgau, Germany  Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine  Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland, Basel, Switzerland  Autoimmunity Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States, Oklahoma City, OK  Department of Biostatistics, UAB School of Public Health, Birmingham, AL, United States, Birmingham, AL  Department of Neurology, Dnipro State Medical University, Dnipro, Ukraine, Dnipro, Ukraine  Clinic of Neurology and Sleep Medicine, Acibadem City Clinic University Hospital Tokuda, Sofia, Bulgaria, Sofia, Bulgaria  First Department of Neurology, St. Anne’s University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic  Multiple Sclerosis Centre of Catalonia, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain , Barcelona, Spain  Sanofi, Gentilly, France, Chilly Mazarin, France  Sanofi, Morristown, NJ, United States, Morristown, NJ  Sanofi, Cambridge, MA, United States, Cambridge, MA  Queen Mary University of London, London, United Kingdom, London, United Kingdom  

Sustained Minimal Symptom Expression in Generalized Myasthenia Gravis: A 120-week Post Hoc Analysis of RAISE-XT

Ofatumumab Treatment Up to Eight Years Shows a Favorable and Consistent Safety Profile in People Living With Relapsing Multiple Sclerosis